Darolutamide plus ADT in Metastatic Hormone-Sensitive Prostate Cancer - The ARASEC Trial - Neal Shore

Details

In this discussion, Neal Shore joins Alicia Morgans in a conversation about a clinical trial for patients with mHSPC, the ARASEC trial. This study is designed to demonstrate how well darolutamide administered together with androgen deprivation therapy works in men with metastatic hormone-sensitive prostate cancer. Biographies: Neal Shore, MD, FACS , is the Medical Director of the Carolina Urologic...